PDCD1 and cancer: The upregulation of CD274 (PD-L1), FAM3C, and other T cell exhaustion markers in NRF2 activated LUAD cancer suggest that they could be the population who can benefit the most from anti-PD1 or anti-PD-L1 therapy.